The FDA has identified "significant data gaps" in the safety record for per- and polyfluoroalkyl substances (PFAS) used in cosmetic products. Bergeson & Campbell, the regulatory law firm that tracks the agency's chemical reviews, surfaced the finding in its latest reporting on FDA action.

The phrase, drawn from the FDA's own framing, signals that the agency does not yet have the toxicological, exposure, or use information required to close out a class-level safety assessment of PFAS in finished personal-care products. In FDA practice, a "data gap" finding means the underlying dossier is too thin to support a yes-or-no conclusion. The agency must now commission studies, request industry submissions, or build the record through post-market surveillance.

For trade readers, the finding is less a verdict than a status update. It confirms that PFAS remain on the FDA's active cosmetics docket and that the next regulatory move is data-driven, not enforcement-driven.

What does the finding change for brands and formulators?

Nothing on the shelf today is being pulled. The FDA has not announced a recall, a ban, or a concentration cap tied to this finding. The agency has put the PFAS file back on the active docket and acknowledged, on the record, that the record is incomplete.

For product developers, compliance leads, and procurement teams, that translates into three near-term workstreams:

• An internal PFAS audit. Any SKU listing a fluorinated surfactant, emulsifier, or film-former needs a line-by-line review once the FDA names the specific compounds driving the data-gap finding.
• Supplier documentation. Expect more requests for impurity profiles, certificates of analysis, and PFAS declarations on ingredients marketed as water-resistant, long-wear, or oil-barrier.
• Claims review. "Fluorine-free" and "PFAS-free" on-pack statements are likely to draw sharper scrutiny as the regulatory conversation narrows.

Why are PFAS hard to replace?

PFAS entered the cosmetics toolbox because they do things few other chemistries can: repel water and oil, spread evenly, form flexible films, and extend wear on skin and lashes. Substitutes typically mean trade-offs in wear time, transfer resistance, or sensory feel, and reformulating is rarely a like-for-like swap.

The class itself is also unusually wide. "PFAS" covers thousands of fluorinated substances rather than a single molecule. Individual ingredients may end up on very different regulatory tracks once the FDA starts parsing the record in detail.

For contract manufacturers, that breadth also complicates benchmarking. A reformulation that swaps one fluorinated polymer for another may look compliant on paper while still sitting inside the PFAS universe the FDA is now scrutinizing.

What comes next?

The immediate question is whether the FDA pairs the data-gap finding with a formal request for industry submissions, a proposed rule, or a guidance document. Bergeson & Campbell's coverage suggests the agency is moving toward a structured data-collection step rather than a unilateral hazard determination. Watch the Federal Register, the FDA's cosmetics guidance page, and forthcoming state-level announcements for the next concrete filing.

For formulators, brand owners, and procurement teams, the message is straightforward: the PFAS file in Washington is open, the regulator has said so on the record, and the next round of paperwork is on its way.